Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NovoTTF-100A with Bevacizumab in Recurrent Glioblastoma
NCT01894061Phase 2Completed
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Sep 2013
- Primary completion
- Jul 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in glioblastoma (GBM), sponsored by Case Comprehensive Cancer Center. Started Sep 2013; status: completed.
02
Drugs
bevacizumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT01894061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01894061.